The value of gallium 67 (Ga) imaging in monitoring lymphoma response to treatment was assessed in 25 patients with Ga-avid tumors and compared to body computed tomography (CT), chest radiographs, and palpation of tumor infiltrated peripheral lymph nodes. Ga imaging was negative in 95% (20/21) of the patients who were clinically considered to be in remission and in whom treatment was stopped. The disease did not recur during a follow-up of 12 to 26 months in 15 patients. Six patients developed recurrence of the disease 3 to 12 months after treatment was stopped. In all six patients Ga imaging became positive again at the time of the appearance of active disease. In the group of patients in remission, CT was negative in 57% (11/19), chest x-rays in 55% (6/11) and peripheral lymph nodes were palpated in none of the patients (13/13). In four patients that did not achieve remission after treatment, Ga scans were positive. Ga imaging appears useful in monitoring lymphoma response to treatment. This is probably because Ga imaging monitors tumor cell viability, whereas body CT and chest radiographs show the tumor mass, which may consist of fibrotic or necrotic tissue.
SummaryA randomised study was carried out in 60 anaesthetised patients with no evidence of airway difficulties, to compare the Williams Airway Intubator and the Ovassapian Fibreoptic Intubating Airway for bronchoscopic view and ease of railroading a tracheal tube during fibreoptic orotracheal intubation. The Williams Airway Intubator provided a better view of the glottis (41 (68.3%) unobstructed views) than the Ovassapian Fibreoptic Intubating Airway (15 (25%) unobstructed views; p < 0.0001) and a shorter time was needed to complete bronchoscopy (median (95% CI) difference 4 s (1-7); p = 0.01). Four (6.7%) bronchoscopies failed using the Williams Airway Intubator compared with 26 (43.3%) using the Ovassapian Fibreoptic Intubating Airway (p < 0.0001). Both airways provided similar intubating conditions when the glottis was visible.
Androgen receptor inhibition by spironolactone and its effect on growth was studied. Eighteen pairs of 3-week-old rats were selected and treated with , 2 mg/kg body weight of spironolactone for 70 days .The rats were pair-fed and measured every 10 days until sacrifice at the age of 90 days. The prostates were removed from 3 pairs of male rats. Androgen receptors in prostatic cytosol of treated rats were diminished by 85% in comparison to control rats. Although this study confirmed a previous finding that spironolactone inhibits androgen receptors in the prostate, it showed no effect on crown-to-tail growth of the rats.The mechanism of growth promotion of androgen may be mediated by growth hormone and/or somatomedin C. It seems that other factors may have an effect on growth. It cannot be ruled out that inhibition of more than 80% of the androgen receptors is needed for growth impairment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.